Maladaptive plasticity of serotonin axon terminals in levodopa-induced dyskinesia

Annals of Neurology

Volumn 68, Issue 5, 2010, Pages 619-628

  Rylander, Daniella ^a   Parent, Martin ^b   O Sullivan, Sean S ^c   Dovero, Sandra ^d   Lees, Andrew J ^c   Bezard, Erwan ^d   Descarries, Laurent ^e   Cenci, M Angela ^a  

^a LUND UNIVERSITY   (Sweden)

^b CENTRE DE RECHERCHE DE L INSTITUT UNIVERSITAIRE EN SANTÉ MENTALE DE QUÉBEC   (Canada)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

^d UNIVERSITÉ DE BORDEAUX   (France)

^e UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BRAIN DERIVED NEUROTROPHIC FACTOR; LEVODOPA; RADIOLIGAND; SEROTONIN; SEROTONIN TRANSPORTER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN TISSUE; CELL MEMBRANE; CELL STIMULATION; CELL STRUCTURE; CELL ULTRASTRUCTURE; CONTROLLED STUDY; CORPUS STRIATUM; DEPOLARIZATION; DOPAMINE RELEASE; DYSKINESIA; FEMALE; HUMAN; HUMAN TISSUE; INNERVATION; MALE; NERVE CELL PLASTICITY; NERVE ENDING; NERVE PROJECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; RAT; SYNAPTIC MEMBRANE;

1-METHYL-4-PHENYL-1,2,3,6-TETRAHYDROPYRIDINE; AGED; ANIMALS; BRAIN-DERIVED NEUROTROPHIC FACTOR; CORPUS STRIATUM; DISEASE MODELS, ANIMAL; DOPAMINE; DYSKINESIA, DRUG-INDUCED; FEMALE; HUMANS; LEVODOPA; MACACA FASCICULARIS; MALE; NEURONAL PLASTICITY; OXIDOPAMINE; PARKINSON DISEASE; PRESYNAPTIC TERMINALS; RADIOLIGAND ASSAY; RATS; RATS, SPRAGUE-DAWLEY; SEROTONIN; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS;

EID: 78249271694     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.22097     Document Type: Article

References (43)

1. Obeso JA, Olanow CW, Nutt JG., Levodopa motor complications in Parkinson-s disease. Trends Neurosci 2000; 23: S2 - S7.
2. Manson A, Schrag A., Levodopa-induced dyskinesias, the clinical problem: clinical features, incidence, risk factors, management and impact on quality of life. In:, Bezard, E, ed. Recent breakthroughs in basal ganglia research. New York, NY: Nova Science Publishers, 2006: 369 - 380.
3. Calabresi P, Giacomini P, Centonze D, et al. Levodopa-induced dyskinesia: a pathological form of striatal synaptic plasticity? Ann Neurol 2000; 47: S60 - S68.
4. Cenci MA, Lindgren HS., Advances in understanding L-DOPA-induced dyskinesia. Curr Opin Neurobiol 2007; 17: 665 - 671.
5. Hirsch EC., Nigrostriatal system plasticity in Parkinson-s disease: effect of dopaminergic denervation and treatment. Ann Neurol 2000; 47: S115 - S120.
6. Cenci MA, Lundblad M., Post- versus presynaptic plasticity in L-DOPA-induced dyskinesia. J Neurochem 2006; 99: 381 - 392.
7. Lindgren HS, Ohlin KE, Cenci MA., Differential involvement of D1 and D2 dopamine receptors in L-DOPA-induced angiogenic activity in a rat model of Parkinson-s disease. Neuropsychopharmacology 2009; 34: 2477 - 2488.
8. Lindgren HS, Andersson DR, Lagerkvist S, et al. L-DOPA-induced dopamine efflux in the striatum and the substantia nigra in a rat model of Parkinson-s disease: temporal and quantitative relationship to the expression of dyskinesia. J Neurochem 2010; 112: 1465 - 1476.
9. Tanaka H, Kannari K, Maeda T, et al. Role of serotonergic neurons in L-DOPA-derived extracellular dopamine in the striatum of 6-OHDA-lesioned rats. Neuroreport 1999; 10: 631 - 634.
10. Navailles S, Bioulac B, Gross C, et al. Serotonergic neurons mediate ectopic release of dopamine induced by l-DOPA in a rat model of Parkinson-s disease. Neurobiol Dis 2010; 38: 136 - 143.
11. Dupre KB, Eskow KL, Barnum CJ, et al. Striatal 5-HT1A receptor stimulation reduces D1 receptor-induced dyskinesia and improves movement in the hemiparkinsonian rat. Neuropharmacology 2008; 55: 1321 - 1328.
12. Zhang X, Andren PE, Greengard P, et al. Evidence for a role of the 5-HT1B receptor and its adaptor protein, p11, in L-DOPA treatment of an animal model of Parkinsonism. Proc Natl Acad Sci U S A 2008; 105: 2163 - 2168.
13. Mamounas LA, Altar CA, Blue ME, et al. BDNF promotes the regenerative sprouting, but not survival, of injured serotonergic axons in the adult rat brain. J Neurosci 2000; 20: 771 - 782.
14. Mattson MP, Maudsley S, Martin B., BDNF and 5-HT: a dynamic duo in age-related neuronal plasticity and neurodegenerative disorders. Trends Neurosci 2004; 27: 589 - 594.
15. Foltynie T, Cheeran B, Williams-Gray CH, et al. BDNF val66met influences time to onset of levodopa induced dyskinesia in Parkinson-s disease. J Neurol Neurosurg Psychiatry 2009; 80: 141 - 144.
16. Guillin O, Diaz J, Carroll P, et al. BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature 2001; 411: 86 - 89.
17. Carta M, Carlsson T, Kirik D, Bjorklund A., Dopamine released from 5-HT terminals is the cause of L-DOPA-induced dyskinesia in Parkinsonian rats. Brain 2007; 130: 1819 - 1833.
18. Carlsson T, Carta M, Winkler C, et al. Serotonin neuron transplants exacerbate L-DOPA-induced dyskinesias in a rat model of Parkinson-s disease. J Neurosci 2007; 27: 8011 - 8022.
19. Descarries L, Soucy JP, Lafaille F, et al. Evaluation of three transporter ligands as quantitative markers of serotonin innervation density in rat brain. Synapse 1995; 21: 131 - 139.
20. Parent M, Wallman M-J, Descarries L., Distribution and ultrastructural features of the serotonin innervation in rat and squirrel monkey subthalamic nucleus. Eur J Neurosci 2010; 31: 1233 - 1242.
21. Goggi J, Pullar IA, Carney SL, et al. Modulation of neurotransmitter release induced by brain-derived neurotrophic factor in rat brain striatal slices in vitro. Brain Res 2002; 941: 34 - 42.
22. Andersson M, Hilbertson A, Cenci MA., Striatal fosB expression is causally linked with l-DOPA-induced abnormal involuntary movements and the associated upregulation of striatal prodynorphin mRNA in a rat model of Parkinson-s disease. Neurobiol Dis 1999; 6: 461 - 474.
23. Westin JE, Vercammen L, Strome EM, et al. Spatiotemporal pattern of striatal ERK1/2 phosphorylation in a rat model of L-DOPA-induced dyskinesia and the role of dopamine D1 receptors. Biol Psychiatry 2007; 62: 800 - 810.
24. Finkelstein DI, Stanic D, Parish CL, et al. Axonal sprouting following lesions of the rat substantia nigra. Neuroscience 2000; 97: 99 - 112.
25. Soghomonian J-J, Descarries L, Watkins KC., Serotonin innervation in adult rat neostriatum. II. Ultrastructural features: a radioautographic and immunocytochemical study. Brain Res 1989; 481: 67 - 86.
26. Descarries L, Mechawar N., Structural organization of monoamine and acetylcholine neuron systems in the rat CNS. In:, Lajtha, A, Vizi, ES, eds. Handbook of neurochemistry and molecular neurobiology. New York, NY: Springer Science+Business Media, 2008: 1 - 20.
27. Dori IE, Dinopoulos A, Parnavelas JG., The development of the synaptic organization of the serotonergic system differs in brain areas with different functions. Exp Neurol 1998; 154: 113 - 125.
28. Kish SJ, Tong J, Hornykiewicz O, et al. Preferential loss of serotonin markers in caudate versus putamen in Parkinson-s disease. Brain 2008; 131: 120 - 131.
29. Linazasoro G., New ideas on the origin of L-dopa-induced dyskinesias: age, genes and neural plasticity. Trends Pharmacol Sci 2005; 26: 391 - 397.
30. Voon V, Fernagut PO, Wickens J, et al. Chronic dopaminergic stimulation in Parkinson-s disease: from dyskinesias to impulse control disorders. Lancet Neurol 2009; 8: 1140 - 1149.
31. Picconi B, Centonze D, Hakansson K, et al. Loss of bidirectional striatal synaptic plasticity in L-DOPA-induced dyskinesia. Nat Neurosci 2003; 6: 501 - 506.
32. Pavese N, Evans AH, Tai YF, et al. Clinical correlates of levodopa-induced dopamine release in Parkinson disease: a PET study. Neurology 2006; 67: 1612 - 1617.
33. de la Fuente-Fernandez R, Sossi V, Huang Z, et al. Levodopa-induced changes in synaptic dopamine levels increase with progression of Parkinson-s disease: implications for dyskinesias. Brain 2004; 127: 2747 - 2754.
34. Meissner W, Ravenscroft P, Reese R, et al. Increased slow oscillatory activity in substantia nigra pars reticulata triggers abnormal involuntary movements in the 6-OHDA-lesioned rat in the presence of excessive extracellular striatal dopamine. Neurobiol Dis 2006; 22: 586 - 598.
35. Buck K, Voehringer P, Ferger B., Site-specific action of l-3,4-dihydroxyphenylalanine in the striatum but not globus pallidus and substantia nigra pars reticulata evokes dyskinetic movements in chronic l-3,4-dihydroxyphenylalanine-treated 6-hydroxydopamine-lesioned rats. Neuroscience 2010; 166: 355 - 358.
36. Carta M, Lindgren HS, Lundblad M, et al. Role of striatal L-DOPA in the production of dyskinesia in 6-hydroxydopamine lesioned rats. J Neurochem 2006; 96: 1718 - 1727.
37. Waterhouse EG, Xu B., New insights into the role of brain-derived neurotrophic factor in synaptic plasticity. Mol Cell Neurosci 2009; 42: 81 - 89.
38. Raab S, Plate KH., Different networks, common growth factors: shared growth factors and receptors of the vascular and the nervous system. Acta Neuropathol 2007; 113: 607 - 626.
39. Sossi V, de la Fuente-Fernandez R, Schulzer M, et al. Age-related differences in levodopa dynamics in Parkinson-s: implications for motor complications. Brain 2006; 129: 1050 - 1058.
40. van Luijtelaar MG, Tonnaer JA, Steinbusch HW., Aging of the serotonergic system in the rat forebrain: an immunocytochemical and neurochemical study. Neurobiol Aging 1992; 13: 201 - 215.
41. Tapia-Arancibia L, Aliaga E, Silhol M, et al. New insights into brain BDNF function in normal aging and Alzheimer disease. Brain Res Rev 2008; 59: 201 - 220.
42. Munoz A, Li Q, Gardoni F, et al. Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia. Brain 2008; 131: 3380 - 3394.
43. Johansson PA, Andersson M, Andersson KE, et al. Alterations in cortical and basal ganglia levels of opioid receptor binding in a rat model of l-DOPA-induced dyskinesia. Neurobiol Dis 2001; 8: 220 - 239.